Barclays
CBIO

Barclays’s Crescent Biopharma CBIO Stock Holding History

Barclays’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-350
Closed -$504K – 7076
2018
Q3 		$504K Hold
350
– – ﹤0.01% 4275
2018
Q2 		$565K Buy
+350
New +$602K ﹤0.01% 3824

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's CBIO Position: Q2 2026 in Review

Barclays reduced its Crescent Biopharma (CBIO) stake by 85% in Q2 2026, selling an estimated $502K and leaving 4,462 shares worth $80.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4143.

Barclays first reported a position in CBIO in Q1 2014 and has held it in 41 quarters since. The position peaked at $1.02M in Q4 2017. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Barclays held 4,462 shares of Crescent Biopharma worth $80.3K as of Q2 2026.
  • Barclays sold 25,727 Crescent Biopharma shares in Q2 2026, an estimated $502K.
  • Crescent Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4143 holding.
  • Barclays first reported a position in Crescent Biopharma in Q1 2014 and has held it in 41 quarters since.
  • Barclays's Crescent Biopharma position peaked at $1.02M in Q4 2017.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.